| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H10O7 |
| Molecular Weight | 302.2357 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC2=C(C(=O)C=C(O2)C3=CC(O)=C(O)C(O)=C3)C(O)=C1
InChI
InChIKey=ARSRJFRKVXALTF-UHFFFAOYSA-N
InChI=1S/C15H10O7/c16-7-3-8(17)14-9(18)5-12(22-13(14)4-7)6-1-10(19)15(21)11(20)2-6/h1-5,16-17,19-21H
Originator
Approval Year
PubMed
Sample Use Guides
Tricetin was administered to four rats at an oral dose of 100 mg which resulted in the urinary excretion of unchanged tricetin, accompanied by small amounts of 3,5-dihydroxyphenylpropionic acid.
Route of Administration:
Oral
Human MCF-7 breast cancer cells were maintained in monolayer cultures at 37 deg-C under a 5% CO2 atmosphere in DMEM supplemented with 10% FCS, 5 micro-g/mL insulin, 100 units/mL of penicillin G, 100 micro-g/mL of streptomycin, and 0.25 micro-g/mL of amphotericin B. Cells were plated in 96-well culture plates, and incubated for 24 hours prior to treatment with various concentrations of triceten and a further 48 hour incubation period. Inhibition of cell proliferation by tricetin was measured by XTT assay. Triceten inhibited the growth of MCF-7 cells in a dose-dependent manner with an IC50 value of 32.17 micro-M.
SUBSTANCE RECORD
